KING OF PRUSSIA, Pa.—MDS Pharma Services announced its launch of a new therapeutic focus on metabolic disorders such as diabetes, dyslipidemia, and obesity, that will leverage the company's expertise in biomarkers and clinical trials involving these disorders. The initiative will be led by Dr. Didier Saur, who brings nearly 20 years of drug industry experience.
"In 2006, about a quarter of our Global Clinical Development revenue is expected to come from work associated with metabolic disorders," said David Spaight, company president. "We have made a strategic decision to become a leader in this arena and have a dedicated team working in metabolic disorders."
Already, the Global Clinical Development division is involved in more than a dozen clinical trials involving metabolic disorders, including cholesterol studies in North and South America and diabetes studies in Europe and the Americas.
